Cancer Patents (Class 530/828)
-
Patent number: 5523393Abstract: The sequence of the protein coding regions of the bcl-2 gene are provided as well as bacterial clones which produce the proteins. Assays are provided for detecting a class of B-cell neoplasms associated with a chromosome translocation between chromosomes 14 and 18. This translocation is involved in the majority of cases of human follicular lymphomas. One assay employs an antibody which is immunoreactive with a human protein which is over-expressed due to the chromosome translocation. Another assay involves measurement of the amount of mRNA which hybridizes to the gene proximal to the translocation break-point.Type: GrantFiled: May 5, 1995Date of Patent: June 4, 1996Assignee: The Wistar InstituteInventors: Yoshihide Tsujimoto, Carlo A. Croce
-
Patent number: 5521285Abstract: The present invention comprises the epitope recognized by the human monoclonal antibody 28A32, the human tumor antigen containing this epitope, which we have identified, isolated and characterized, and human MCA 28A32. The invention also relates to the use of antibodies to the antigen containing this epitope for diagnosis and monitoring of treatment of cancer and to the use of this antigen in the preparation of vaccines to elicit an immune response similar to that obtained against tumor cells containing this epitope.Type: GrantFiled: April 1, 1993Date of Patent: May 28, 1996Assignee: Akzo Nobel N.V.Inventors: Nicholas Pomato, Ebo S. Bos, Janet H. Ransom, Michael G. Hanna, Jr.
-
Patent number: 5514600Abstract: The invention provides a method for detecting the presence of ARD 1 protein in a sample. The method includes the steps of providing labeled or immobilized anti-ARD 1 antibody in a reaction zone, introducing sample into the reaction zone such that ARD 1 protein in the sample, if present, will react with said antibody to form an immunological complex, and detecting the formation of said immunological complex. Cells, nucleotide and amino acid sequences and vectors associated with ARD 1 are also described.Type: GrantFiled: September 27, 1994Date of Patent: May 7, 1996Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Joel Moss, Koichi Mishima, Maria S. Nightingale, Mikako Tsuchiya
-
Patent number: 5506119Abstract: The presence of certain extracellular regions ("ECR") from human and rat variants of the CD44 membrane glycoprotein have been found to be associated with metastasis ability in tumor cells. Isolated polynucleotides encoding the ECRs permit expression of the ECR polypeptide, which in turn can be used as an antigen to obtain monoclonal antibodies that recognize the ECR polypeptide. The anti-ECR monoclonal antibodies have the ability to prevent metastasis by tumor cells that would otherwise metastasize and spread.Type: GrantFiled: November 9, 1992Date of Patent: April 9, 1996Assignees: Kernforschungszentrum Karlsruhe GmbH, Universitaet Karlsruhe, Deutsches KrebsforschungszentrumInventors: Peter Herrlich, Helmut Ponta, Ursula Guenthert, Siegfried Matzku, Achim Wenzel
-
Patent number: 5478556Abstract: A breast cancer vaccine which comprises a mixture of tumor associated antigens (TAA) with low doses of recombinant interleukin-2 (IL-2) and granulocyte-macrophage colony stimulating factor (GM-CSF).Type: GrantFiled: February 28, 1994Date of Patent: December 26, 1995Inventors: Robert L. Elliott, Jonathan F. Head
-
Patent number: 5470970Abstract: An isolated DNA encoding a polypeptide substantially identical to maspin (SEQ ID NO:1); a substantially purified preparation of maspin; an antibody specific for maspin; and use of such DNAs and antibodies in diagnostic, screening, and therapeutic methods.Type: GrantFiled: September 1, 1993Date of Patent: November 28, 1995Assignee: Dana-Farber Cancer Institute, Inc.Inventors: Ruth Sager, Anthony Anisowicz, Zhiqiang Zou
-
Patent number: 5464751Abstract: A purified proteinaceous substance bindable with p185, the translation product of the neu oncogene is disclosed. The purified proteinaceous substance may be characterized in that it increases the activity of the tyrosine kinase contained in the neu oncogene product but does not increase the activity of tyrosine kinase of epidermal growth factor receptor; induces p185 dimerization and internalization; affects the growth of cells which express p185 in a dose dependent manner; is heat stable from about 56.degree. C. to about 100.degree. C.; is degradable by protease; and has a molecular weight of from about 7,000 to about 14,000 daltons in its smallest active form as determined by gel filtration and ultrafiltration membrane analysis. Methods of detecting p185 on the surfaces of tumor cells are also disclosed.Type: GrantFiled: September 24, 1992Date of Patent: November 7, 1995Assignee: Trustees of the University of PennsylvaniaInventors: Mark I. Greene, Kunio Dobashi, James G. Davis, Junji Hamuro
-
Patent number: 5459251Abstract: The sequence of the protein coding regions of the bcl-2 gene are provided as well as bacterial clones which produce the proteins. Assays are provided for detecting a class of B-cell neoplasms associated with a chromosome translocation between chromosomes 14 and 18. This translocation is involved in the majority of cases of human follicular lymphomas. One assay employs an antibody which is immunoreactive with a human protein which is over-expressed due to the chromosome translocation. Another assay involves measurement of the amount of mRNA which hybridizes to the gene proximal to the translocation break-point.Type: GrantFiled: April 18, 1994Date of Patent: October 17, 1995Assignee: The Wistar InstituteInventors: Yoshihide Tsujimoto, Carlo A. Croce
-
Patent number: 5459035Abstract: A method is described for identifying and localizing tumors in a patient. The method comprises assaying extracellular fluids, isolated from a patient, for the presence of elevated levels of ring shaped particles (RSP). The assay employs binding labeled RSP specific binding agent to the RSP.Type: GrantFiled: December 9, 1992Date of Patent: October 17, 1995Assignee: AMDL, Inc.Inventors: Robert R. Guerrero, Donald E. Rounds
-
Patent number: 5451664Abstract: An isolated and purified substance called Acta having the following features: (a) a molecular weight of 60 kd to 70 kd in SDS-PAGE using 12.5% gel, (b) reacts with a monoclonal antibody which is secreted by hybridoma FERM BP-3482, (c) binds to chymotrypsin and (d) binds to DNA. Acta is used to diagnose cancer and Alzheimer's disease.Type: GrantFiled: December 20, 1993Date of Patent: September 19, 1995Assignee: Konica CorporationInventors: Masahiko Yamasaki, Numa Masayuki
-
Patent number: 5376530Abstract: A previously isolated hepatitis B virus (HBV) integration in a 147 bp cellular DNA fragment linked to hepatocellular carcinoma (HCC) was used as a probe to clone the corresponding complementary DNA from a human liver cDNA library. Nucleotide sequence analysis revealed that the overall structure of the cellular gene, which has been named hap, is similar to that of the DNA-binding hormone receptors. Six out of seven hepatoma and hepatoma-derived cell-lines express a 2.5 kb hap mRNA species which is undetectable in normal adult and fetal livers, but present in all non-hepatic tissues analyzed. Low stringency hybridization experiments revealed the existence of hap related genes in the human genome. The cloned DNA sequence is useful in the preparation of pure hap protein and as a probe in the detection and isolation of complementary DNA and RNA sequences. The hap protein is a retinoic acid (RA) receptor identified as RAR-.beta.. The RAR-.beta.Type: GrantFiled: July 22, 1993Date of Patent: December 27, 1994Assignee: Institut PasteurInventors: Hughes B. De The, Agnes Marchio, Pierre Tiollais, Anne DeJean, Nigel Brand, Martin Petkovich, Andree Krust, Pierre Chambon
-
Patent number: 5359031Abstract: The present invention involves a method for detecting bladder cancer in a subject. The method preferably comprises first collecting a urine sample from the subject. The presence of a proteinaceous substance having a molecular weight of about 180 kDa according to its relative electrophoretic migration rate through detergent-containing polyacrylamide gel is then measured. This substance reversibly binds concanavalin A and is complexed with gamma globulin while in the urine. The gamma globulin complex binds to Staphlococcal protein A. Said proteinaceous substance, when present in detectable amount, is an indicator of bladder cancer.Type: GrantFiled: April 28, 1992Date of Patent: October 25, 1994Assignee: Board of Regents, The University of Texas SystemInventors: Haiyen E. Zhau, Richard J. Babaian
-
Patent number: 5330896Abstract: A monoclonal antibody recognizing an autocrine growth factor that reacts with activated lymphocytes and cancer cells is described. The growth factor, a small glycoprotein is distinct from interleukin 2 and other known growth factors by function, structure and tissue distribution. A homologous growth factor is present in lymphoid tissues of a wide range of vertebrate species. Diagnostic and therapeutic uses of the growth factor and antibody-growth factor complex are disclosed. Also disclosed are therapeutic uses of synthetic analogues and peptide derivatives of the antigen.Type: GrantFiled: January 10, 1990Date of Patent: July 19, 1994Inventor: Ronald J. Billing
-
Patent number: 5324822Abstract: A method of isolation of a material with similar immunological properties to CA-195 from human amniotic fluid has been disclosed. This material can be substituted for CA-195 in many processes, for example in the preparation of analytical control materials.Type: GrantFiled: December 21, 1992Date of Patent: June 28, 1994Assignee: Ciba Corning Diagnostics Corp.Inventor: Thomas H. Duffy
-
Patent number: 5288614Abstract: In order to aid in the detection of malignant diseases the sample of a body fluid is incubated with at least two receptors R.sub.1 and R.sub.2 in which a signal change is produced by binding of at least the receptors R.sub.1 and R.sub.2 to the substance to be detected in the sample solution and in which one of the two receptors contains a monoclonal antibody which binds to the amino acid sequence 311 to 335 of cytokeratin 19 and the other receptor contains a monoclonal antibody which binds to the amino acid sequence 346 to 359 of cytokeratin 19 and the signal change in the sample caused by the binding is determined.Type: GrantFiled: July 23, 1991Date of Patent: February 22, 1994Assignee: Boehringer Mannheim GmbHInventors: Heinz Bodenmuller, Andreas Dessauer
-
Patent number: 5281697Abstract: Disclosed is a protein that specifically binds carcinoembryonic actigen (CEA) in the presence of divalent cation in vitro. This protein has a molecular weight of about 20 kD as determined by SDS-polyacrylamide gel electrophoresis, is glycosylated, and includes the amino acid sequence set forth in the Sequence Listing as SEQ ID NO:4. Also disclosed are antibodies that recognize the CEA binding protein, methods of detecting carcinoma, methods of treating carcinoma, and a kit for screening a patient for carcinoma.Type: GrantFiled: May 31, 1991Date of Patent: January 25, 1994Assignees: Applied Biotechnology, Inc., New England Deacons Hospital Corp.Inventors: Carol A. Toth, Peter Thomas, Sibusisiwe M. Maswoswe, Joseph V. Briggman
-
Patent number: 5278290Abstract: Disclosed is a protein that specifically binds carcinoembryonic actigen (CEA) in the presence of divalent cation in vitro. This protein has a molecular weight of about 21 kD as determined by SDS-polyacrylamide gel electrophoresis, is glycosylated, and includes the amino acid sequence set forth in the Sequence Listing as SEQ ID NO: 2. Also disclosed are antibodies that recognize the CEA binding protein, methods of detecting carcinoma, methods of treating carcinoma, and a kit for screening a patient for carcinoma.Type: GrantFiled: May 31, 1991Date of Patent: January 11, 1994Assignees: Applied Biotechnology, Inc., New England Deaconess Hospital, Corp.Inventors: Peter Thomas, Carol A. Toth, Sibusisiwe M. Maswoswe, Joseph V. Briggman
-
Patent number: 5268169Abstract: A method of treating ovarian cancer in warm-blooded animals comprising intraperitoneally administering to warm-blooded animals by perfusion a recombinant polypeptide of human gamma interferon type with a specific activity at least equal to 1.times.10.sup.7 U/mg in an anti-cancer effective amount.Type: GrantFiled: April 13, 1992Date of Patent: December 7, 1993Assignee: Roussel UclafInventors: Maud Brandely, Danielle Lando
-
Patent number: 5245017Abstract: Disclosed are methods of isolating a protein which binds carcinoembryonic antigen. These methods include the following steps. A biological sample containing carcinoembryonic antigen (CEA) and a CEA-binding protein (CBP) is provided and contacted with a divalent cation at a concentration and for a time sufficient to allow the binding of the CBP to CEA, thereby forming a CBP-CEA conjugate. The sample is then contacted with an adsorbent that binds CEA for a time sufficient to allow adsorbance to the adsorbent. Portions of the sample not adsorbed are removed. The CBP is then disassociated from the conjugate and is collected.Type: GrantFiled: May 31, 1991Date of Patent: September 14, 1993Assignees: Applied Biotechnology, Inc., New England Deaconess Hospital CorporationInventors: Sibusisiwe M. Maswoswe, Joseph V. Briggman, Carol A. Toth, Peter Thomas
-
Patent number: 5234839Abstract: Compositions useful for detecting ras gene proteins are described consisting of GTP and a protein having an apparent reduced molecular weight of about 115,000-120,000 daltons, or fragments derived therefrom, that stimulate ras protein guanosine triphosphatase activity. Also described are methods whereby the compositions are used to identify cancer therapeutics.Type: GrantFiled: March 20, 1991Date of Patent: August 10, 1993Assignee: Cetus Oncology CorporationInventors: Frank P. McCormick, Kirston E. Koths, Robert F. Halenbeck, Mary M. Trahey
-
Patent number: 5223606Abstract: A previously isolated hepatitis B virus (HBV) integration in a 147 bp cellular DNA fragment linked to hepatocellular carcinoma (HCC) was used as a probe to clone the corresponding complementary DNA from a human liver cDNA library. Nucleotide sequence analysis revealed that the overall structure of the cellular gene, which has been named hap, is similar to that of the DNA-binding hormone receptors. Six out of seven hepatoma and hepatoma-derived cell-lines express a 2.5 kb hap mRNA species which is undetectable in normal adult and fetal livers, but present in all non-hepatic tissues analyzed. Low stringency hybridization experiments revealed the existence of hap related genes in the human genome. The cloned DNA sequence is useful in the preparation of pure hap protein and as a probe in the detection and isolation of complementary DNA and RNA sequences.Type: GrantFiled: December 17, 1987Date of Patent: June 29, 1993Assignee: Institut PasteurInventors: Hughes Blaudin de The, Agnes Marchio, Pierre Tiollais, Anne DeJean
-
Patent number: 5223412Abstract: Microbially produced ice nucleator mixtures which include either cell-free ice nucleator particle mixtures and/or whole cell ice nucleator mixtures. These mixtures are produced in methods which comprises culturing a selected microorganism in a two step process at a first temperature in a first step and at a lower temperature in a second step. The mciroorganisms include Erwinia, Pseudomonas and Escherichia coil. These methods produce ice nucleator mixtures having increased concentrations of ice nucleating sites per given weight or volume of ice nucleator material.Type: GrantFiled: February 21, 1991Date of Patent: June 29, 1993Assignee: Genencor International, Inc.Inventors: David R. Wight, Wayne R. Newman, Patrick J. Ward, Kristine Pochodylo
-
Patent number: 5221622Abstract: A novel 170 kD membrane protease is isolated from malignant human melanoma cell line LOX and RPMI7951. The protease is useful in a method of diagnosing cellular transformation.Type: GrantFiled: October 11, 1990Date of Patent: June 22, 1993Assignee: The Board of Regents of Georgetown UniversityInventor: Wen-Tien Chen
-
Patent number: 5204450Abstract: Disclosed is a glycoprotein, CORA, which has a binding affinity for carcinoembryonic antigen (CEA). This glycoprotein is a marker for carcinoma, and can be characterized by having a molecular weight of about 46,000-50,000 daltons, an isoelectric point of about 3.0-3.5, a carbohydrate content of about 25-35% by weight, reactivity with antisera raised thereto, and substantially no reactivity with antisera raised to nonspecific cross-reacting antigen (NCA) or to CEA. Also disclosed are a hybridoma which produces a monoclonal antibody to CORA, the monoclonal antibody to CORA, and a device, kit, and method for detecting and monitoring carcinoma.Type: GrantFiled: January 9, 1990Date of Patent: April 20, 1993Assignee: New England Deaconess Hospital CorporationInventors: Carol A. Toth, Peter Thomas
-
Patent number: 5202429Abstract: The sequence of the protein coding regions of the bcl-2 gene are provided as well as bacterial clones which produce the proteins. Assays are provided for detecting a class of B-cell neoplasms associated with a chromosome translocation between chromosomes 14 and 18. The translocation is involved in the majority of cases of human follicular lymphomas. One assay employs an antibody which is immunoreactive with a human protein which is over-expressed due to the chromosome translocation. Another assay involves measurement of the amount of mRNA which hybridizes to the gene proximal to the translocation break-point.Type: GrantFiled: March 19, 1991Date of Patent: April 13, 1993Assignee: The Wistar InstituteInventors: Yoshihide Tsujimoto, Carlo A. Croce
-
Patent number: 5196334Abstract: A process is provided for purifying Urogenital Sinus Derived Growth Inhibitory Factor (UGIF) from embryonic tissue which comprises chromatographing medium from cultures of embryonic tissue derived from the urogenital sinus by gel filtration chromotography. Further purification by reverse phase high pressure liquid chromotography is also demonstrated. The UGIF is obtained in 70-fold to 8000-fold purification over the conditioned medium. A UGIF composition of matter is also provided.Type: GrantFiled: September 2, 1988Date of Patent: March 23, 1993Assignee: Baylor College of MedicineInventors: David R. Rowley, Donald J. Tindall, Sr.
-
Patent number: 5185254Abstract: A tumor-associated antigen, GA733-1, has been discovered which shares sequence homology with both thyroglobulin type I and interleukin-2 receptors. The antigen is highly expressed in pancreatic carcinoma cells. The antigen is similar to a previously described tumor-associated antigen found in colorectal carcinoma cells. The gene for the antigen is fully sequenced and described here.Type: GrantFiled: December 29, 1988Date of Patent: February 9, 1993Assignee: The Wistar InstituteInventor: Alban Linnenbach
-
Patent number: 5171666Abstract: The present invention relates to a novel tumor-associated antigen that is a cell-surface glycoprotein having a molecular weight in the range of 110,000-140,000 daltons that is present in a variety of carcinomas, including squamous cell carcinomas and adenocarcinomas. The invention also comprises antibodies reactive with the antigen, hybridoma cell lines that produce the antibodies of the invention, and methods for using the antibodies in the diagnosis and treatment of cancer.Type: GrantFiled: October 19, 1988Date of Patent: December 15, 1992Assignee: Eli Lilly and CompanyInventors: Magda C. Gutowski, David A. Johnson
-
Patent number: 5151266Abstract: Methods are disclosed for increasing the solubility of antibodies and their radioisotope, toxin, or drug immunoconjugates and for reducing the non-specific uptake of antibody, either conjugated or unconjugated, into the RES organs such as via Fc receptor-mediated mechanisms. The methods involve incubation of the reactive component with amphipathic molecules, such as an anionic detergent, to achieve the desired result. A preferred anionic detergent in this regard is sodium dodecylsulfate.Type: GrantFiled: December 22, 1988Date of Patent: September 29, 1992Assignee: NeoRx CorporationInventors: A. Charles Morgan, Jr., Gowsala Pavanasasivam
-
Patent number: 5134075Abstract: The present invention is concerned with a novel monoclonal antibody which binds strongly to a protein antigen associated with human tumors, including carcinomas of the colon, breast, ovary and lung, as well as melanomas and sarcomas. The antibody binds to normal human cells to a much lesser degree than to tumor cells. The antibody finds use both in diagnostic methods such as the detection of malignant cells associated with tumors and in therapeutic methods for treatment of humans with tumors. Also disclosed is a novel 100,000 dalton glycoprotein antigen found on the cell surface of human tumor cells. The amino terminal amino acid sequence of this antigen is: ##STR1## in which X represents an unidentified amino acid.Type: GrantFiled: February 17, 1989Date of Patent: July 28, 1992Assignee: Oncogen Limited PartnershipInventors: Karl E. Hellstrom, Ingegerd Hellstrom, Hans Marquardt, Yoshitaka Yoneyama
-
Patent number: 5110911Abstract: Human tumor associated Thomsen-Friedenreich (TF) antigen is purified from adenocarcinoma conditioned media, adenocarcinoma cell detergent extracts or plural effusion fluid by affinity chromatography using an insolubilized TF-specific monoclonal antibody, MAb 49H.8. The TF antigen is a glycoprotein characterized by a non-cryptic Gal .beta.(1.fwdarw.3) GalNAc epitope, a molecular weight in excess of 1,000,000 daltons, and extractability with perchloric acid, the epitope being sensitive to alkali and periodate but resistant to acid. A heterologous sandwich immunoassay has been developed for human TF antigen using a monoclonal antibody as the catcher and labelled peanut agglutinin as the probe. Since human TF antigen is shed by tumor cells, a positive determination of the TF antigen in a patient sample indicates the presence of cancer.Type: GrantFiled: November 2, 1989Date of Patent: May 5, 1992Assignee: Biomira, Inc.Inventors: John Samuel, B. Michael Longenecker
-
Patent number: 5109115Abstract: The present invention discloses anti-bombesin monoclonal antibody and a method of detecting autocrine growth factor. A method and kit for screening and controlling growth of human SCLC has also been disclosed.Type: GrantFiled: December 5, 1988Date of Patent: April 28, 1992Assignee: The United States of America as represented by the Secretary of the Dept. of Health & Human ServicesInventors: Frank F. Cuttitta, John D. Minna
-
Patent number: 5108987Abstract: Conjugates of transferrin or ceruloplasmin with anti-tumour agents. Such conjugates are useful in the treatment of tumours. Suitable anti-tumour agents include adriamycin, daunomycin, methotrexate, vincristin, 6-mercaptopurine, cytosine arabinoside and cyclophosphamide. Transferrin or ceruloplasmin in preferably coupled to the anti-tumour agent by means of glutaraldehyde.Type: GrantFiled: July 31, 1989Date of Patent: April 28, 1992Inventor: Ward P. Faulk
-
Patent number: 5106731Abstract: The present invention relates to a growth factor found in HTLV-II conditioned media and to compositions containing same. The growth factor of the present invention supports the growth of Kaposi's sarcoma endothelial-like cells. The factor has a molecular weight of 30K to 35K in monomeric form and a molecular weight of about 70K in dimeric form.Type: GrantFiled: October 21, 1988Date of Patent: April 21, 1992Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Syed Z. Salahuddin, Shuji Nakamura, Robert C. Gallo
-
Patent number: 5104975Abstract: Compositions useful for detecting ras gene proteins are described consisting of GTP and a protein having an apparent reduced molecular weight of about 115,000-120,000 daltons, or fragments derived therefrom, that stimulate ras protein guanosine triphosphatase activity. Also described are methods whereby the compositions are used to identify cancer therapeutics.Type: GrantFiled: July 8, 1988Date of Patent: April 14, 1992Assignee: Cetus CorporationInventors: Francis P. McCormick, Kirston E. Koths, Robert F. Halenbeck, Mary M. Trahey
-
Patent number: 5091178Abstract: A method for identifying and using antibodies which are directed against tumor-associated glycolipid antigens and which are capable of activating serum complement or antibody dependent cellular cytotoxicity. These antibodies find use in the therapy of tumors. Administration of the antibodies results in lysis of the tumor cells in vivo.Type: GrantFiled: January 30, 1990Date of Patent: February 25, 1992Assignee: OncogenInventors: Karl E. Hellstrom, Ingegerd Hellstrom
-
Patent number: 5091177Abstract: The present invention is concerned with novel monoclonal antibodies which define a glycolipid antigen associated with human non-small cell lung carcinomas ("NSCLC") and certain other human carcinomas. The antibodies bind to normal human cells to a much lesser degree than to tumor cells. The antibodies find use in diagnostic methods such as the detection of malignant cells associated with NSCLC and in therapeutic methods. The invention also comprises a method for determining the presence of a malignant condition in lung tissue and other human tissue. The method involves examining the human tissue for the presence of a glycolipid antigen having the characteristics of a ganglio-N-triosylceramide.Type: GrantFiled: May 11, 1990Date of Patent: February 25, 1992Assignee: OncogenInventors: Ingegerd Hellstrom, Joseph P. Brown, Karl E. Hellstrom, Diane Horn, Peter Linsley
-
Patent number: 5078996Abstract: Macrophages and precursor monocytes are activated to exhibit tumoricidal activity by stimulation solely with granulocyte-macrophage colony stimulating factor. A patient suffering from tumors can be treated by direct administration of therapeutically effective quantities of activated granulocyte-macrophage colony stimulating factor. Homogeneous granulocyte-macrophage colony stimulating factor for use in activating macrophages and monocyte precursors is prepared by recombinant DNA techniques. The gene coding for granylocyte-macrophage colony stimulating factor is isolated and then recombinant protein product expressed in an appropriate expression system. The granulocyte-macrophage colony stimulating factor recovered from the expression system is purified to homogeneity by reverse phase high-performance liquid chromatography.Type: GrantFiled: July 31, 1986Date of Patent: January 7, 1992Assignee: Immunex CorporationInventors: Paul J. Conlon, III, Kenneth H. Grabstein
-
Patent number: 5066579Abstract: A recombinant peptide antigen is provided which is derived from HTLV-I envelope protein gp46 and immunoreactive with anti-HTLV-I antibody present in a individuals with HTLV-I related T-cell leukemia. The antigen is useful as a diagnostic tool in determining whether an individual has been or is infected with HTLV-I, and is also useful in a method of immunizing individuals against such infection.Type: GrantFiled: June 13, 1989Date of Patent: November 19, 1991Assignee: Genelabs IncorporatedInventor: Gregory R. Reyes
-
Patent number: 5053224Abstract: A method of inducing an immunological response to solid tumors is provided wherein anti-idiotype antibodies presenting an internal image of a tumor or antigen are administered to a patient. Monoclonal anti-idiotype antibodies and immortal B lymphocytes that produce them are also provided.Type: GrantFiled: August 26, 1987Date of Patent: October 1, 1991Inventors: Hilary Koprowski, Dorothee Herlyn, Elaine C. DeFreitas
-
Patent number: 5053489Abstract: A carbohydrate-free polypeptide coded for by a human DNA sequence of 309 nucleotides is immunologically reactive with monoclonal antibody against the human DF3 breast carcinoma-associated antigen. The nucleotide sequence is also useful as a probe to reveal restriction fragment length polymorphisms in human DNA.Type: GrantFiled: January 27, 1989Date of Patent: October 1, 1991Assignee: Dana-Farber Cancer Institute, Inc.Inventor: Donald W. Kufe
-
Patent number: 5043340Abstract: Derivatives of 4-desacetyl VLB C-3 carboxhydrazide, active anti-tumor agents and useful as intermediates for active anti-tumor conjugates.Type: GrantFiled: April 3, 1990Date of Patent: August 27, 1991Assignee: Eli Lilly and CompanyInventor: George J. Cullinan
-
Patent number: 5030621Abstract: A human anti-cancer vaccine is prepared by culturing human cancer cells, such as human melanoma cells, human lung cancer cells, human colon cancer cells, human breast cancer cells, and other human cancer cells in a serum-free medium. The cells are selected on the basis of expressing different patterns of cell surface tumor antigens and are adapted to and are grown in a serum-free medium. During culturing antigens of the cancer cells are shed into the culture medium. The culture medium, containing the shed cancer cell antigens, is then concentrated, such as by vacuum ultrafiltration. In some instances the vaccine is then treated with a non-ionic surfactant or detergent, such as Nonidet P-40 (NP-40), to break up aggregates and treated with a presevative, such as sodium azide, and then subjected to ultracentrifugation.Type: GrantFiled: February 22, 1990Date of Patent: July 9, 1991Inventor: Jean-Claude Bystryn
-
Patent number: 5030559Abstract: Disclosed are monoclonal antibodies which react with human tumor cells, particularly metastatic human tumor cells, but not with normal human tissues tested. The monoclonal antibodies are prepared against a 580 kilodalton glycoprotein antigen, designated gp580, which is isolated from either rat or human tumor cells. Methods for isolating the glycoprotein antigen are disclosed as well. Moreover, techniques are disclosed for utilizing these antibodies both in the detection and in the prevention of human tumor lesions.Type: GrantFiled: April 1, 1986Date of Patent: July 9, 1991Assignee: Board of Regents, The University of Texas SystemInventors: Garth L. Nicolson, Susan M. North, Peter A. Steck
-
Patent number: 5021553Abstract: A monoclonal antibody against human cancer, characterized in that the monoclonal antibody is produced by a hybridoma cell line obtained from the fusion of B-lymphocyte immunized with cells of human cancer origin and tumor cells, and reactive with cancer cells from more than one organ but substantially not reactive with normal cells, and a process for production thereof; and a hybridoma cell line used to produce the above-mentioned monoclonal antibody, and a process for production thereof.Type: GrantFiled: July 10, 1989Date of Patent: June 4, 1991Assignee: Wakunaga Seiyaka Kabushiki KaishaInventors: Eiichi Tahara, Atsushi Ochiai, Hiroshi Yokozaki, Toyoharu Hozumi, Eikai Kyo
-
Patent number: 5019648Abstract: A hybrid cell line is developed which produces a monoclonal antibody which binds to a unique antigenic site expressed on the surface of phagocytic cells. The monoclonal antibody binds to and activates a specific domain of the CD11b glycoprotein so as to inhibit adhesion dependent functions of the phagocytic cell, but it does not affect other phagocytic functions. This monoclonal antibody can be used as a reactant in an in vitro diagnostic immunoassay for detecting the unique antigenic site on the surface of normal human neutrophils.Type: GrantFiled: March 7, 1988Date of Patent: May 28, 1991Assignee: Dana-Farber Cancer InstituteInventors: Stuart F. Schlossman, James D. Griffin
-
Patent number: 5019497Abstract: Methods and compositions are provided for detecting antigens having a specific epitope associated with squamous lung carcinoma. The antigen may be found at lesion sites or in the blood as indicative of the squamous lung carcinoma.Specific antibodies may be used for the detection of the antigen and in therapy.The mouse hybridoma 43-9F producing IgM monoclonal antibody 43-9F and SLC cell RH-SLC-L11 were deposited at The PHLS Centre for Applied Microbiology and Research, Porton Down, Salisbury, U.K. on Jan. 31, 1985 and given Accession Nos. 85013101 and 85061403, respectively.Type: GrantFiled: July 5, 1988Date of Patent: May 28, 1991Inventor: Lennart Olsson
-
Patent number: 5015568Abstract: The sequence of the protein coding regions of the bcl-2 gene are provided as well as bacterial clones which produce the proteins. Assays are provided for detecting a class of B-cell neoplasms associated with a chromosome translocation between chromosomes 14 and 18. This translocation is involved in the majority of cases of human follicular lymphomas. One assay employs an antibody which is immunoreactive with a human protein which is over-expressed due to the chromosome translocation. Another assay involves measurement of the amount of mRNA which hybridizes to the gene proximal to the translocation break-point.Type: GrantFiled: July 9, 1986Date of Patent: May 14, 1991Assignee: The Wistar InstituteInventors: Yoshihide Tsujimoto, Carlo A. Croce
-
Patent number: 5013645Abstract: Disclosed are immunological methods and materials for detection of antigens associated with breast or prostate cancer disease states. Presently preferred antibody preparations (e.g., PR92 monoclonal antibodies produced by hybridoma cell line ATCC HB 9390) are employed in immunoassays performed on patient body fluids and for purification of tumor-associated antigen compositions.Type: GrantFiled: March 23, 1988Date of Patent: May 7, 1991Assignee: Abbott LaboratoriesInventor: Yung D. Kim
-
Patent number: RE35171Abstract: Compositions useful for detecting ras gene proteins are described consisting of GTP and a protein having an apparent reduced molecular weight of about 115,000-120,000 daltons, or fragments derived therefrom, that stimulate ras protein guanosine triphosphatase activity. Also described are methods whereby the compositions are used to identify cancer therapeutics.Type: GrantFiled: April 14, 1994Date of Patent: March 5, 1996Assignee: Cetus Oncology CorporationInventors: Francis P. McCormick, Kirston E. Koths, Robert F. Halenbeck, Mary M. Trahey